This woman with the most aggressive form of cancer have received a greater advantage when the disease development stalled for nearly six months. "Avastin", also known as bevacizumab, is already widely used in patients with colon cancer, and doctors believe this drug will become the standard for the treatment of ovarian cancer.

Principal investigator Dr. Tim Perrin Consultant - oncologist at the Institute of Oncology, St. James, and Honorary Senior Lecturer at the University of Leeds, said: "These results are very encouraging, especially for women with advanced ovarian cancer."

The researchers analyzed the medical records of victims of ovarian cancer in 1528, which were sent to either the standard chemotherapy, either in their treatment included "Avastin". After 28 months follow-up results of a second embodiment of the treatment showed a significant slowing of disease progression.